AG-120 (ivosidenib), a first in-class mutant IDH1 inhibitor, promotes morphologic changes and upregulates liver-specific genes in IDH1 mutant cholangiocarcinoma

被引：3
|
作者：
Ishii, Yuko [1 ]
Sigel, Carlie [2 ]
Lowery, Maeve A. [2 ]
Goyal, Lipika [3 ]
Gliser, Camelia [1 ]
Jiang, Liewen [1 ]
Pandya, Susan [1 ]
Bin Wu [1 ]
Choe, Sung [1 ]
Deshpande, Vikram [3 ]
机构：
[1] Agios Pharmaceut Inc, Cambridge, MA USA
[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[3] Massachusetts Gen Hosp, Boston, MA 02114 USA
来源：
MOLECULAR CANCER THERAPEUTICS | 2018年 / 17卷 / 01期
关键词：
D O I：
10.1158/1535-7163.TARG-17-A071
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A071
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers
    Popovici-Muller, Janeta
    Lemieux, Rene M.
    Artin, Erin
    Saunders, Jeffrey O.
    Salituro, Francesco G.
    Travins, Jeremy
    Cianchetta, Giovanni
    Cai, Zhenwei
    Zhou, Ding
    Cui, Dawei
    Chen, Ping
    Straley, Kimberly
    Tobin, Erica
    Wang, Fang
    David, Muriel D.
    Penard-Lacronique, Virginie
    Quivoron, Cyril
    Saada, Veronique
    De Botton, Stephane
    Gross, Stefan
    Dang, Lenny
    Yang, Hua
    Utley, Luke
    Chen, Yue
    Kim, Hyeryun
    Jin, Shengfang
    Gu, Zhiwei
    Yao, Gui
    Luo, Zhiyong
    Lv, Xiaobing
    Fang, Cheng
    Yan, Liping
    Olaharski, Andrew
    Silverman, Lee
    Biller, Scott
    Su, Shin-San M.
    Yen, Katharine
    ACS MEDICINAL CHEMISTRY LETTERS, 2018, 9 (04): : 300 - 305
  • [2] Discovery of AG-120: A first-in-class inhibitor of IDH1 mutant enzymes for the treatment of cancers harboring IDH1 mutations
    Popovici-Muller, Janeta
    Lemieux, Rene
    Saunders, Jeffrey
    Salituro, Francesco
    Yen, Katharine
    Straley, Kimberly
    Tobin, Erica
    Wang, Fang
    Gross, Stefan
    Artin, Erin
    Dang, Lenny
    Yang, Hua
    Utley, Luke
    Chen, Yue
    Olaharski, Andrew
    Silverman, Lee
    Agresta, Sam
    Su, Michael
    Biller, Scott
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 252
  • [3] Ivosidenib for IDH1 Mutant Cholangiocarcinoma: A Narrative Review
    Sumbly, Vikram
    Landry, Ian
    Rizzo, Vincent
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (01)
  • [4] Functional characterization of the ivosidenib (AG-120) and azacitidine combination in a mutant IDH1 AML cell model
    Yen, Katharine
    Chopra, Vivek S.
    Tobin, Erica
    Avanzino, Brian
    Mavrommatis, Konstantinos
    DiMartino, Jorge
    MacBeth, Kyle J.
    CANCER RESEARCH, 2018, 78 (13)
  • [5] THE IDH1 MUTANT INHIBITOR AG-120 SHOWS STRONG INHIBITION OF 2-HG PRODUCTION IN AN ORTHOTOPIC IDH1 MUTANT GLIOMA MODEL IN VIVO
    Nicolay, Brandon
    Narayanaswamy, Rohini
    Aguado, Elia
    Nagaraja, Raj
    Murtie, Josh
    Liu, Guowen
    Ishii, Yuko
    NEURO-ONCOLOGY, 2017, 19 : 86 - 86
  • [6] Genetic Profiling and Deep IDH1 Mutation Clearance to ≤0.04% in Ivosidenib (AG-120)-Treated Patients with Mutant IDH1 Relapsed or Refractory and Untreated AML
    Stone, Richard M.
    Choe, Sung
    Zhang, Vickie
    Marteyn, Benoit
    Penard-Lacronique, Virginie
    Wang, Hongfang
    DiNardo, Courtney D.
    Stein, Eytan M.
    Fathi, Amir T.
    Tallman, Martin S.
    Kantarjian, Hagop M.
    Attar, Eyal C.
    Wu, Bin
    de Botton, Stephane
    BLOOD, 2017, 130
  • [7] AG-120, A FIRST-IN-CLASS MUTANT IDH1 INHIBITOR IN PATIENTS WITH RECURRENT OR PROGRESSIVE IDH1 MUTANT GLIOMA: UPDATED RESULTS FROM THE PHASE 1 NON-ENHANCING GLIOMA POPULATION
    Mellinghoff, Ingo K.
    Touat, Mehdi
    Maher, Elizabeth
    De la Fuente, Macarena
    Cloughesy, Timothy F.
    Holdhoff, Matthias
    Cote, Gregory M.
    Burris, Howard
    Janku, Filip
    Huang, Ray
    Young, Robert J.
    Ellingson, Benjamin
    Nimkar, Tara
    Jiang, Liewen
    Ishii, Yuko
    Choe, Sung
    Fan, Bin
    Steelman, Lori
    Yen, Katharine
    Bowden, Chris
    Pandya, Susan
    Wen, Patrick Y.
    NEURO-ONCOLOGY, 2017, 19 : 10 - 11
  • [8] Ivosidenib (AG-120) in Mutant IDH1 Relapsed/Refractory Acute Myeloid Leukemia: Results of a Phase 1 Study
    DiNardo, Courtney D.
    Stein, Eytan M.
    de Botton, Stephane
    Roboz, Gail J.
    Altman, Jessica K.
    Mims, Alice S.
    Swords, Ronan
    Collins, Robert H.
    Mannis, Gabriel N.
    Pollyea, Daniel A.
    Donnellan, Will
    Fathi, Amir T.
    Pigneux, Arnaud
    Erba, Harry P.
    Prince, Gabrielle T.
    Stein, Anthony S.
    Uy, Geoffrey L.
    Foran, James M.
    Traer, Elie
    Stuart, Robert K.
    Arellano, Martha L.
    Slack, James L.
    Sekeres, Mikkael A.
    Willekens, Christophe
    Choe, Sung
    Wang, Hongfang
    Zhang, Vickie
    Yen, Katharine E.
    Kapsalis, Stephanie M.
    Yang, Hua
    Dai, David
    Fan, Bin
    Goldwasser, Meredith
    Liu, Hua
    Agresta, Sam
    Wu, Bin
    Attar, Eyal C.
    Tallman, Martin S.
    Stone, Richard M.
    Kantarjian, Hagop M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S204 - S205
  • [9] Determination of IDH1 Mutational Burden and Clearance Via Next-Generation Sequencing in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Inhibitor of Mutant IDH1
    DiNardo, Courtney D.
    de Botton, Stephane
    Stein, Eytan M.
    Roboz, Gail J.
    Swords, Ronan T.
    Pollyea, Daniel A.
    Fathi, Amir T.
    Collins, Robert
    Altman, Jessica K.
    Flinn, Ian W.
    Mannis, Gabriel N.
    Mims, Alice S.
    Foran, James M.
    Pigneux, Arnaud
    Prince, Gabrielle T.
    Uy, Geoffrey L.
    Tallman, Martin S.
    Kantarjian, Hagop M.
    Liu, Hua
    Attar, Eyal C.
    Sacolick, Jennifer
    Yen, Katharine
    Hurov, Jonathan B.
    Choe, Sung
    Wu, Bin
    Stone, Richard M.
    BLOOD, 2016, 128 (22)
  • [10] Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120
    Birendra, K. C.
    DiNardo, Courtney D.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2016, 16 (08): : 460 - 465
12345